IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates.

Department of Psychiatry and Center for Basic Neuroscience, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9070, USA.
Nature Neuroscience (Impact Factor: 14.98). 02/2007; 10(1):93-9. DOI: 10.1038/nn1812
Source: PubMed

ABSTRACT Chronic morphine administration (via subcutaneous pellet) decreases the size of dopamine neurons in the ventral tegmental area (VTA), a key reward region in the brain, yet the molecular basis and functional consequences of this effect are unknown. In this study, we used viral-mediated gene transfer in rat to show that chronic morphine-induced downregulation of the insulin receptor substrate 2 (IRS2)-thymoma viral proto-oncogene (Akt) signaling pathway in the VTA mediates the decrease in dopamine cell size seen after morphine exposure and that this downregulation diminishes morphine reward, as measured by conditioned place preference. We further show that the reduction in size of VTA dopamine neurons persists up to 2 weeks after morphine withdrawal, which parallels the tolerance to morphine's rewarding effects caused by previous chronic morphine exposure. These findings directly implicate the IRS2-Akt signaling pathway as a critical regulator of dopamine cell morphology and opiate reward.

Download full-text


Available from: David W Self, Jun 18, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous results from our lab suggest that hypofunctioning of the serotonergic (5-HT) dorsal raphe nucleus (DRN) is involved in stress-induced opiate reinstatement. To further investigate the effects of morphine dependence and withdrawal on the 5-HT DRN system, we measured gene expression at the level of mRNA in the DRN during a model of morphine dependence, withdrawal and post withdrawal stress exposure in rats. Morphine pellets were implanted for 72h and then either removed or animals were injected with naloxone to produce spontaneous or precipitated withdrawal, respectively. Animals exposed to these conditions exhibited withdrawal symptoms including weight loss, wet dog shakes and jumping behavior. Gene expression for brain-derived neurotrophic factor (BDNF), TrkB, corticotrophin releasing-factor (CRF)-R1, CRF-R2, GABAA-α1, μ-opioid receptor (MOR), 5-HT1A, tryptophan hydroxylase2 and the 5-HT transporter was then measured using quantitative real-time PCR at multiple time-points across the model of morphine exposure, withdrawal and post withdrawal stress. Expression levels of BDNF, TrkB and CRF-R1 mRNA were decreased during both morphine exposure and following seven days of withdrawal. CRF-R2 mRNA expression was elevated after seven days of withdrawal. 5-HT1A receptor mRNA expression was decreased following 3 hours of morphine exposure, while TPH2 mRNA expression was decreased after seven days of withdrawal with swim stress. There were no changes in the expression of GABAA-α1, MOR or 5-HT transporter mRNA. Collectively these results suggest that alterations in neurotrophin support, CRF-dependent stress signaling, 5-HT synthesis and release may underlie 5-HT DRN hypofunction that can potentially lead to stress-induced opiate relapse.
    Neuroscience 09/2013; 254. DOI:10.1016/j.neuroscience.2013.08.071 · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the firing activity of dopamine (DA) neurons in the ventral tegmental area (VTA) and the behavioral response to morphine rewarding properties alter as opiate withdrawal, little is known about the dynamic changes in DA signal pathway from the VTA to the nucleus accumbens (NAc) during prolonged withdrawal, and whether the changes are indicative of vulnerability to relapse of drug abuse. Here we report that morphine spontaneously withdrawn (SW) rats are incapable of responding to small dose of morphine-induced conditioned place preference (CPP) from 24h-SW to 30d-SW, but recover response at 45d-SW. Interestingly, mesoaccumbens DA signaling, including the firing of DA neurons in the VTA, contents of DA and its metabolic ratio, and the membrane level of dopamine D1 receptor in the NAc elicited by morphine challenge, display a similar pattern of time-dependent changes during morphine withdrawal. Moreover, blockade of D1 receptor abolishes this behavioral transition. In addition, a strong correlation was found between % change in CPP score and membrane D1 receptor level induced by morphine challenge. These results indicate a time-dependent behavioral switch from tolerance to sensitization during the prolonged withdrawal, which could offer a window for therapeutic intervention via manipulations of D1 receptors.
    Brain Structure and Function 06/2013; 219(5). DOI:10.1007/s00429-013-0599-2 · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psychostimulants robustly induce alterations in neuronal structural plasticity throughout brain reward circuits. However, despite our extensive understanding of how these circuits modulate motivated behavior, it is still unclear whether structural plasticity within these regions drives pathological behavioral responses in addiction. Although these structural changes have been subjected to an exhaustive phenomenological characterization, we still have a limited understanding of the molecular mechanisms regulating their induction and the functional relevance of such changes in mediating addiction-like behavior. Here we have highlighted the known molecular pathways and intracellular signaling cascades that regulate psychostimulant-induced changes in neuronal morphology and synaptic restructur-ing, and we discuss them in the larger context of addiction behavior. A ddiction is characterized by persistent drug-seeking behavior and a high frequency of relapse. The repercussions of such drug seeking and relapse behavior place a strong economic, social, and health burden on all levels of soci-ety. In fact, the World Drug Report estimates that 5% of the world's population use illicit drugs, placing a suggested socioeconomic bur-den of several hundred billion U.S. dollars an-nually (UNODC 2010). Unfortunately, there are still relatively few effective therapeutic in-terventions available for the treatment of sub-stance abuse. This has led to a concerted effort to reveal the molecular and cellular basis of addiction (Hyman and Malenka 2001; Nestler 2001, 2004; Koob and Le Moal 2005; Hyman et al. 2006; Kauer and Malenka 2007; Kalivas 2009; Luscher and Malenka 2011; Wolf 2011), to enable the development of novel pharma-cotherapeutic agents and treatment strategies (Nestler 2002; O'Brien 2008; Wessell and Ed-wards 2010). A defining hallmark of drug abuse is com-pulsive and persistent drug-seeking behavior at the expense of negative emotional, physical, and social consequences. This persistent behavior has led to the hypothesis that drugs of abuse have the capacity to provoke long-lasting changes to the brain, which underlie pervasive and uncontrolled addiction-related behavioral phenotypes. This is supported by findings that chronic exposure to all known addictive sub-stances results in dramatically altered patterns of gene expression in key brain reward centers. Similarly, early investigations established that one of the more robust forms of neuronal
    Cold Spring Harbor Perspectives in Medicine 08/2012; DOI:10.1101/cshperspect.a011957 · 7.56 Impact Factor